Baseline characteristics, vaccination history of patients and healthy controls, and anti-CD20 B-cell depletion history of patients in the study
| Baseline characteristics | |||
| Patients | Healthy volunteers | P value | |
| n=65 | n=26 | ||
| Male sex (%) | 33 (51%) | 10 (38%) | 0.3 |
| Median age in years | 66 (54, 73) | 53 (45, 60) | 0.002 |
| Vaccine (BioNTech/Pfizer) (%) | 41 (63%) | 8 (31%) | 0.005 |
| Time between second vaccine dose and V2 Visit (months) | 5.97 (5.23, 6.87) | 6.75 (5.97, 7.16) | 0.075 |
| Time between third vaccine dose and V2 Visit (months) | 1.15 (1.00, 1.31) | – | |
| Months between V1 and V2 visit (months) | 3.90 (3.50, 4.43) | 4.57 (4.35, 5.03) | 0.004 |
| Cumulative dose anti-CD20 (g) | 3.00 (1.60, 5.00) | – | |
| Time between last anti-CD20 therapy and last vaccine dose (years) | 1.26 (0.24, 3.68) | – | |
| Indication for anti-CD20 therapy | <0.001 | ||
| Autoimmune disease | 45 (69%) | – | |
| Haematological cancer | 5 (7.7%) | – | |
| Kidney transplantation | 15 (23%) | – | |
| Immunosuppressive co-medication | |||
| Any | 41 (63%) | – | |
| Any corticosteroids within last 6 months | 32 (49%) | – | |
| Prednisolone equivalent >0 mg to 2.5 mg daily at follow-up | 13 (20%) | – | |
| Prednisolone equivalent >2.5 mg to 5 mg daily at follow-up | 10 (15%) | – | |
| Prednisolone equivalent >5 mg daily at follow-up | 0 (0%) | – | |
| Calcineurin inhibitors | 17 (26%) | – | |
| Antimetabolites | 21 (32%) | – | |
| Methotrexate | 2 (3%) | – | |
| Cytotoxic chemotherapy | 1 (1%) | – | |
| Other | 3 (5%) | – | |